Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Adipose Inflammation and Endothelial Function in Obesity
NCT04907214Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in obesity, prediabetes, sponsored by Vanderbilt University Medical Center. Started Jul 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT04907214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907214.